Related Experiment Video
Updated: Mar 29, 2026
Preparation of Naringenin Solution for In Vivo Application
Published on: August 10, 2021
Effects of Naringenin in Preclinical Models of Breast Cancer
Emily C Irwin1, Newman Siu Kwan Sze1, Evangelia Tsiani1,2
1Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada.
Abstract:
Breast cancer is the most commonly diagnosed cancer among women, with approximately one in eight women developing the disease during their lifetime. Despite advancements in current treatment options, breast cancer was responsible for an estimated 670,000 deaths worldwide in 2022. This highlights the urgent need for the development of novel therapeutic strategies. Historically, plant-derived compounds have played a significant role in cancer therapy, exemplified by widely used chemotherapeutic agents such as paclitaxel and docetaxel. In recent years, increasing attention has been directed toward novel plant-derived compounds as potential anti-cancer agents. Among these, Naringenin, a flavonoid predominantly found in citrus fruits, has shown promising antioxidant, anti-inflammatory, and anti-cancer properties. This review highlights recent studies investigating the effects of Naringenin and its derivatives on breast cancer. Evidence from both in vitro and in vivo animal models suggests that Naringenin may exert anti-tumor activity by inhibiting cell proliferation, promoting apoptosis, modulating key cell signaling pathways, and enhancing radio-sensitivity in breast cancer cells. Although preclinical evidence strongly supports the anticancer potential of Naringenin in breast cancer, comprehensive clinical studies are urgently needed to validate its efficacy and safety in humans.
Insights
Naringenin, a citrus flavonoid, shows potential in fighting breast cancer by inhibiting tumor growth and promoting cell death. Further clinical research is needed to confirm its effectiveness and safety in humans.
Area of Science:
- Oncology
- Pharmacology
- Natural Products Chemistry
Background:
- Breast cancer remains a leading cause of death in women globally, necessitating novel therapeutic approaches.
- Plant-derived compounds have historically contributed significantly to cancer treatment, with ongoing research into new agents.
- Naringenin, a flavonoid from citrus fruits, exhibits antioxidant, anti-inflammatory, and anti-cancer properties.
Purpose of the Study:
- To review recent research on the effects of Naringenin and its derivatives on breast cancer.
- To evaluate the potential of Naringenin as an anti-cancer agent for breast cancer therapy.
Main Methods:
- Review of in vitro studies on Naringenin's effects on breast cancer cells.
- Analysis of in vivo animal models investigating Naringenin's anti-tumor activity.
- Examination of Naringenin's impact on cell proliferation, apoptosis, and signaling pathways.
Main Results:
- Naringenin demonstrated anti-tumor activity in preclinical models.
- It was found to inhibit breast cancer cell proliferation and induce apoptosis.
- Naringenin modulated key cell signaling pathways and enhanced radio-sensitivity in breast cancer cells.
Conclusions:
- Preclinical data suggest Naringenin possesses significant anti-cancer potential against breast cancer.
- Naringenin may offer a novel therapeutic strategy for breast cancer treatment.
- Clinical trials are essential to validate the efficacy and safety of Naringenin in human breast cancer patients.
